Based on the TriSalus Life Sciences Inc. stock forecast from 6 analysts, the average analyst target price for TriSalus Life Sciences Inc. is USD 10.79 over the next 12 months. TriSalus Life Sciences Inc.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of TriSalus Life Sciences Inc. is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, TriSalus Life Sciences Inc.’s stock price was USD 5.77. TriSalus Life Sciences Inc.’s stock price has changed by +2.12% over the past week, +17.76% over the past month and -37.28% over the last year.
No recent analyst target price found for TriSalus Life Sciences Inc.
No recent average analyst rating found for TriSalus Life Sciences Inc.
Company Overview TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. Read Less
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as th...Read More
Frequently Asked Questions About TriSalus Life Sciences Inc. (TLSI) Stock
Based on ratings from 6 analysts TriSalus Life Sciences Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on TLSI's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for TLSI is USD 10.79 over the next 12 months. The maximum analyst target price is USD 12.5 while the minimum anlayst target price is USD 10.
TLSI stock's Price/Earning ratio is 0.08.
Our analysis grades TLSI stock's Price / Earning ratio at B. This means that TLSI stock's Price/Earning ratio is above 14% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this TLSI may be undervalued for its sector.
The last closing price of TLSI's stock was USD 5.77.
The most recent market capitalization for TLSI is USD 0.17B.
Based on targets from 6 analysts, the average taret price for TLSI is projected at USD 10.79 over the next 12 months.
This means that TLSI's stock price may go up by +86.93% over the next 12 months.
We can't find any ETFs which contains TriSalus Life Sciences Inc.'s stock.
As per our most recent records TriSalus Life Sciences Inc. has 116 Employees.
TriSalus Life Sciences Inc.'s registered address is 6272 West 91st Avenue, Westminster, CO, United States, 80031.
You can get more information about it from TriSalus Life Sciences Inc.'s website at https://trisaluslifesci.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About TriSalus Life Sciences Inc. (TLSI) Stock
Based on ratings from 6 analysts TriSalus Life Sciences Inc.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on TLSI's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for TLSI is USD 10.79 over the next 12 months. The maximum analyst target price is USD 12.5 while the minimum anlayst target price is USD 10.
TLSI stock's Price/Earning ratio is 0.08.
Our analysis grades TLSI stock's Price / Earning ratio at B. This means that TLSI stock's Price/Earning ratio is above 14% of the stocks in the Medical Devices sector in the NSD exchange.
Based on this TLSI may be undervalued for its sector.
The last closing price of TLSI's stock was USD 5.77.
The most recent market capitalization for TLSI is USD 0.17B.
Based on targets from 6 analysts, the average taret price for TLSI is projected at USD 10.79 over the next 12 months.
This means that TLSI's stock price may go up by +86.93% over the next 12 months.
We can't find any ETFs which contains TriSalus Life Sciences Inc.'s stock.
As per our most recent records TriSalus Life Sciences Inc. has 116 Employees.
TriSalus Life Sciences Inc.'s registered address is 6272 West 91st Avenue, Westminster, CO, United States, 80031.
You can get more information about it from TriSalus Life Sciences Inc.'s website at https://trisaluslifesci.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TLSI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
